A company signs a CRADA with a DOE national laboratory, or wins an SBIR award, and assumes the hard part is over. Federal validation is in hand, so commercialization should follow soon after.
That assumption is where a lot of companies run into trouble. A DOE partnership is a genuinely valuable asset, but it was never designed to be a shortcut to market. Understanding what these engagements actually deliver, and what they don’t, is the difference between using one well and being disappointed by it.
When it works, a DOE relationship gives a company real, lasting value:
A signed CRADA or a federal award tells investors and future partners that a serious federal entity has looked at your technology and found it worth engaging with.
National laboratories hold research infrastructure and technical expertise that would take years and enormous capital to build independently.
A first engagement, even a small one, often opens the path to further conversations, additional programs, or a stronger position when applying for funding down the line.
These are real outcomes. They are just not the same thing as commercialization.
A DOE partnership, on its own, generally does not guarantee:
Deep or fast technical collaboration on your timeline rather than the lab’s
Follow-on funding, even when the initial engagement goes well
Sole ownership of new intellectual property that comes out of the work
A direct or fast path from lab validation to a commercial product in market
Companies that expect the agreement itself to produce these outcomes are usually the ones left frustrated. The agreement opens a door. It does not walk you through it.
National laboratories operate under a different set of incentives than a commercial partner would. Most are government-owned but contractor-operated, and each one is evaluated on mission delivery rather than on the commercial success of the private companies it works with.
That creates a few predictable patterns. Labs tend toward a cautious, gatekeeper posture with unproven technology, since validating something carefully carries less institutional risk than building alongside a company as a true partner.
Unfunded CRADAs, which are common, come with no financial pressure to move quickly, so government resources are naturally prioritized toward funded work first. And the financial and reputational risk of an engagement that goes nowhere sits almost entirely with the company, not the lab, which shapes how cautiously lab staff engage from day one.
On intellectual property specifically, the standard pattern is not full company ownership. When joint IP does emerge from a CRADA, mutual ownership with a license back to DOE is typical. Labs tend to view that arrangement favorably, since it supports their own mission of moving technology out into industry rather than holding it inside government walls.
Part of the mismatch comes from treating every DOE mechanism as if it exists to do the same job. Each one is built for a different stage of a company’s development:
CRADAs are best suited to validating or co-developing early-stage technology alongside lab expertise and facilities, not to producing a market-ready product.
SBIR and STTR grants provide non-dilutive funding for feasibility work and prototyping, in phases, for small businesses developing a specific innovation.
Office of Energy Dominance Financing loans and loan guarantees, issued under the Title 17 program, are built for capital-intensive projects that are ready for commercial-scale deployment, not early validation.
None of these mechanisms was designed to carry a company the entire distance from concept to market by itself. Commercialization usually requires stitching several of them together over time, in the right order, alongside a company’s own capital and go-to-market work.
The companies that get real value out of DOE relationships are the ones that set expectations internally before they sign anything. A national lab partnership is a long-horizon relationship-building exercise, not a near-term return on investment.
Boards and executive teams that understand this going in tend to stay engaged through the slow middle stretch that most of these partnerships pass through. Boards that were sold on a fast path to revenue tend to lose patience exactly when the relationship most needs continued support, often right before it starts producing something useful.
A DOE engagement moves a company closer to market when a few things are true. There is a named owner on both sides with a defined scope of work, even if no funding is attached.
There is a genuine technical champion inside the lab who has a personal stake in the outcome, not just an administrative sponsor keeping the paperwork current.
And the company has a plan for what comes after the current mechanism, whether that means applying for a Phase II SBIR award, pursuing financing once the technology is closer to deployment, or negotiating a more commercially standard agreement through a lab’s ACT program.
A DOE partnership is a credibility milestone and a research accelerator. It is not a substitute for a company’s own commercialization strategy. Companies that treat it as one piece of a longer plan, rather than the plan itself, are the ones who end up using these relationships well.
Shepherd Strategies helps companies build that longer plan, from choosing the right mechanism at the right stage to setting realistic expectations with leadership before the first agreement is even signed. Organizations weighing a DOE partnership, or already inside one that isn’t delivering what they expected, can reach out through ShepherdStrategies.com to start that conversation
© 2026 Shepherd Strategies LLC.
All Rights Reserved.
